FFO
CATX icon

Fortitude Family Office’s Perspective Therapeutics CATX Stock Holding History

Fortitude Family Office’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-93
Closed -$388 – 2284
2026
Q1 		$388 Buy
+93
New +$393 ﹤0.01% 1803

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Fortitude Family Office's CATX Position: Q2 2026 in Review

Fortitude Family Office sold out of Perspective Therapeutics (CATX) in Q2 2026, closing a stake of 93 shares — an estimated $388 sold.

Fortitude Family Office first reported a position in CATX in Q1 2026 and held it in 1 quarter. The position peaked at $388 in Q1 2026. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Fortitude Family Office reported no remaining Perspective Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fortitude Family Office sold 93 Perspective Therapeutics shares in Q2 2026, an estimated $388.
  • Fortitude Family Office first reported a position in Perspective Therapeutics in Q1 2026 and held it in 1 quarter.
  • Fortitude Family Office's Perspective Therapeutics position peaked at $388 in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.